NDC product
Livalo
NDC 66869-404 · Kowa Pharmaceuticals America, Inc.
Key facts
| Product NDC | 66869-404 |
|---|---|
| Proprietary name | Livalo |
| Nonproprietary name | pitavastatin calcium |
| Substances | PITAVASTATIN CALCIUM |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Kowa Pharmaceuticals America, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA022363 |
| Pharmacologic classes | HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA] |
| Marketing start | May 16, 2019 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: